GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Inventories, Raw Materials & Components

NurExone Biologic (TSXV:NRX) Inventories, Raw Materials & Components : C$0.00 Mil (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Inventories, Raw Materials & Components?

NurExone Biologic's inventories, raw materials & components for the quarter that ended in Sep. 2024 was C$0.00 Mil.


NurExone Biologic Inventories, Raw Materials & Components Historical Data

The historical data trend for NurExone Biologic's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Inventories, Raw Materials & Components Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
- - -

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NurExone Biologic Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


NurExone Biologic Business Description

Industry
Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.
Executives
James Angus Wilson (bilkstys-) Richardson 10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines